Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma.

Magi A, Masselli M, Sala C, Guerriero A, Laise P, Puccini B, Rigacci L, Breschi C, Crociani O, Pillozzi S, Arcangeli A.

Sci Rep. 2019 Jun 13;9(1):8586. doi: 10.1038/s41598-019-44661-x.

2.

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.

Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. No abstract available.

PMID:
31080169
3.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Apr 2. pii: theoncologist.2018-0603. doi: 10.1634/theoncologist.2018-0603. [Epub ahead of print]

PMID:
30940746
4.

Focal spleen lesions in visceral leishmaniasis, a neglected manifestation of a neglected disease: report of three cases and systematic review of literature.

Rinaldi F, Giachè S, Spinicci M, Corsi P, Ambu S, Gianfaldoni G, Rigacci L, Arena U, Bartoloni A, Zammarchi L.

Infection. 2019 Feb 15. doi: 10.1007/s15010-019-01279-5. [Epub ahead of print] Review.

PMID:
30771194
5.

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey.

Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A.

J Blood Med. 2018 Dec 27;10:21-27. doi: 10.2147/JBM.S186786. eCollection 2019. Erratum in: J Blood Med. 2019 Feb 08;10:69.

6.

Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma.

Zinzani PL, Santoro A, Chiti A, Lastoria S, Pinto A, Rigacci L, Barosi G, Pennisi M, Corradini P.

Leuk Lymphoma. 2019 May;60(5):1204-1213. doi: 10.1080/10428194.2018.1519808. Epub 2018 Oct 15.

PMID:
30322329
7.

Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.

Cencini E, Sicuranza A, Fabbri A, Ferrigno I, Rigacci L, Cox MC, Raspadori D, Bocchia M.

Br J Haematol. 2019 Jan;184(2):223-231. doi: 10.1111/bjh.15582. Epub 2018 Sep 11.

PMID:
30203425
8.

The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas.

Rigacci L, Kovalchuk S, Berti V, Puccini B, Mannelli L, Benelli G, Dini C, Pupi A, Bosi A.

World J Nucl Med. 2018 Jul-Sep;17(3):157-165. doi: 10.4103/wjnm.WJNM_42_17.

9.

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.

Ambrosio MR, Lazzi S, Bello GL, Santi R, Porro LD, de Santi MM, Guazzo R, Mundo L, Rigacci L, Kovalchuck S, Onyango N, Fabbri A, Cencini E, Zinzani PL, Zaja F, Angrilli F, Stelitano C, Cabras MG, Spataro G, Bob R, Menter T, Granai M, Cevenini G, Naresh KN, Stein H, Sabattini E, Leoncini L.

Haematologica. 2019 Jan;104(1):e25-e28. doi: 10.3324/haematol.2018.195958. Epub 2018 Jun 28. No abstract available.

10.

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V.

Haematologica. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22.

11.

Diffusion-Weighted and Perfusion-Weighted MRI to Evaluate Therapeutic Response in Lymphoma: A Comparison with FDG-PET/CT.

Calistri L, Puccini B, Berti V, Grazzini G, Nardi C, Rigacci L, Colagrande S.

Acta Haematol. 2018;139(2):74-76. doi: 10.1159/000485548. Epub 2018 Jan 26. No abstract available.

PMID:
29393082
12.

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.

Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F.

Ann Oncol. 2018 Mar 1;29(3):707-714. doi: 10.1093/annonc/mdx764.

PMID:
29253068
13.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

14.

Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience.

Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, Coppini R, Girolami F, Mazzarotto F, Chiostri M, Milli M, Marchionni N, Castelli G.

Eur J Heart Fail. 2018 May;20(5):898-906. doi: 10.1002/ejhf.1049. Epub 2017 Nov 16.

15.

Activation of the aryl hydrocarbon receptor and risk of lymphoma subtypes.

Sanna S, Satta G, Padoan M, Piro S, Gambelunghe A, Miligi L, Ferri GM, Magnani C, Muzi G, Rigacci L, Cabras MG, Angelucci E, Latte GC, Gabbas A, Ennas MG, Cocco P.

Int J Mol Epidemiol Genet. 2017 Sep 1;8(4):40-44. eCollection 2017.

16.

Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.

Cencini E, Puccini B, Rigacci L, Fabbri A, Kovalchuk S, Mannelli L, Benelli G, Carfagno T, Simontacchi G, Bocchia M, Bosi A.

Leuk Lymphoma. 2018 Jun;59(6):1420-1426. doi: 10.1080/10428194.2017.1387909. Epub 2017 Oct 10.

PMID:
28994343
17.

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.

Galimberti S, Ciabatti E, Ercolano G, Grassi S, Guerrini F, Cecconi N, Rousseau M, Cervetti G, Mazziotta F, Iovino L, Falzetti F, Falcinelli F, Bosi A, Rigacci L, Kovalchuk S, Vallisa D, Macchia L, Ciancia E, Petrini M.

Front Pharmacol. 2017 Jun 29;8:413. doi: 10.3389/fphar.2017.00413. eCollection 2017.

18.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.

Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

PMID:
28668386
19.

Role of core needle biopsy in primary breast lymphoma.

Bicchierai G, Rigacci L, Miele V, Meattini I, De Benedetto D, Selvi V, Bianchi S, Livi L, Nori J.

Radiol Med. 2017 Sep;122(9):651-655. doi: 10.1007/s11547-017-0773-3. Epub 2017 May 16.

PMID:
28510806
20.

Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.

Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri AJM, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Giovanella L, Zucca E, Johnson PWM.

Br J Haematol. 2017 Aug;178(4):588-591. doi: 10.1111/bjh.14728. Epub 2017 May 9.

PMID:
28485042
21.

Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.

Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, Viviani S, Rigacci L, Trentin L, Rusconi C, Luminari S, Cantonetti M, Bolis S, Borra A, Darcourt J, Salvi F, Subocz E, Tajer J, Kulikowski W, Malkowski B, Zaucha JM, Gallamini A.

J Nucl Med. 2017 Aug;58(8):1249-1254. doi: 10.2967/jnumed.116.184218. Epub 2017 Jan 26.

22.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U.

Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.

PMID:
27927586
23.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA.

Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

PMID:
27692305
24.

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, Jaccard A, Pol S, Carrat F, Ferretti VV, Visco C, Hermine O.

Blood. 2016 Nov 24;128(21):2527-2532. Epub 2016 Sep 7.

25.

The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Vitolo U.

Leuk Lymphoma. 2017 Jan;58(1):226-229. Epub 2016 Jun 2. No abstract available.

PMID:
27252040
26.

The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).

Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A.

Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28.

PMID:
27133138
27.

Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy.

Ciammella P, Filippi AR, Simontacchi G, Buglione M, Furlan C, Spina M, Tucci A, Rigacci L, Iotti C, Vitolo U, Ricardi U, Merli F.

Leuk Lymphoma. 2016 Nov;57(11):2677-80. doi: 10.3109/10428194.2016.1153088. Epub 2016 Mar 1. No abstract available.

PMID:
26926887
28.

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A.

J Clin Oncol. 2016 Apr 20;34(12):1376-85. doi: 10.1200/JCO.2015.63.0699. Epub 2016 Feb 16.

29.

Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.

Zinzani PL, Pellegrini C, Cerciello G, Monaco F, Volpetti S, Peli A, Angelucci E, Corradini P, Cox MC, Guarini A, Musso M, Bresciani P, Amato G, Billio A, Caparrotti G, Figuera A, Nassi L, Gaudio F, Grossi A, Onida F, Merli M, Rigacci L, Argnani L.

Leuk Lymphoma. 2016 Oct;57(10):2370-4. doi: 10.3109/10428194.2015.1137292. Epub 2016 Feb 17.

PMID:
26732313
30.

Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.

Zinzani PL, Pellegrini C, Cantonetti M, Re A, Pinto A, Pavone V, Rigacci L, Celli M, Broccoli A, Argnani L, Pulsoni A.

Oncologist. 2015 Dec;20(12):1413-6. doi: 10.1634/theoncologist.2015-0227. Epub 2015 Oct 23.

31.

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.

Cencini E, Fabbri A, Rigacci L, Lazzi S, Gini G, Cox MC, Mancuso S, Abruzzese E, Kovalchuk S, Goteri G, Di Napoli A, Bono R, Fratoni S, Di Lollo S, Bosi A, Leoncini L, Bocchia M.

Hematol Oncol. 2017 Mar;35(1):69-78. doi: 10.1002/hon.2249. Epub 2015 Aug 7.

PMID:
26251194
32.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli F, Pinotti G, Mannina D, Luminari S, Stathis A, Russo E, Cavalli F, Giovanella L, Johnson PW, Zucca E.

Blood. 2015 Aug 20;126(8):950-6. doi: 10.1182/blood-2014-12-616474. Epub 2015 Jun 18.

33.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

34.

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.

Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA.

Haematologica. 2015 Apr;100(4):517-24. doi: 10.3324/haematol.2014.108183. Epub 2015 Jan 16.

35.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.

36.

Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.

Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M.

Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14.

37.

Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U.

Leuk Lymphoma. 2015 Jun;56(6):1671-6. doi: 10.3109/10428194.2014.964702. Epub 2014 Nov 19.

PMID:
25241999
38.

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).

Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M; Italian Lymphoma Foundation (FIL).

Leuk Lymphoma. 2015 Apr;56(4):921-6. doi: 10.3109/10428194.2014.953142. Epub 2014 Oct 9.

PMID:
25110825
39.

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Davies A, Cavalli F, Giovanella L, Johnson PW.

J Clin Oncol. 2014 Jun 10;32(17):1769-75. doi: 10.1200/JCO.2013.51.7524. Epub 2014 May 5.

PMID:
24799481
40.

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A.

Ann Oncol. 2014 Jul;25(7):1404-10. doi: 10.1093/annonc/mdu166. Epub 2014 May 5.

PMID:
24799461
41.

Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.

Rigacci L, Puccini B, Kovalchuk S, Fabbri E, Bonizzoni E, Perrone T, Bosi A.

Support Care Cancer. 2014 Sep;22(9):2557-61. doi: 10.1007/s00520-014-2237-9. Epub 2014 Apr 17.

42.

Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions.

Baldini S, Carrai V, Puccini B, Rigacci L, Alterini R, Bosi A.

Transfus Med. 2014 Apr;24(2):125-6. doi: 10.1111/tme.12106. Epub 2014 Feb 7. No abstract available.

PMID:
24720383
43.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M.

Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.

44.

Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.

Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M, Pimpinelli N; Gruppo Italiano Linfomi Cutanei (GILC).

Eur J Haematol. 2014 Aug;93(2):129-36. doi: 10.1111/ejh.12315. Epub 2014 Apr 4.

PMID:
24635751
45.

The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.

Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U.

Leuk Lymphoma. 2015 Jan;56(1):12-25. doi: 10.3109/10428194.2014.894187. Epub 2014 Mar 24. Review.

PMID:
24559287
46.

Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.

Nobili S, Napoli C, Puccini B, Landini I, Perrone G, Brugia M, Benelli G, Doria M, Martelli M, Finolezzi E, Di Rocco A, Del Fava E, Rigacci L, Di Lollo S, Bosi A, Mini E.

Leuk Lymphoma. 2014 Sep;55(9):2071-8. doi: 10.3109/10428194.2013.866665. Epub 2014 Feb 24.

PMID:
24289107
47.

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.

Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D'Arco AM, Musto P, Chiappella A, Baldini L, Bonfichi M, Arcaini L.

Haematologica. 2014 Mar;99(3):489-96. doi: 10.3324/haematol.2013.094318. Epub 2013 Nov 22.

48.

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.

Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi.

Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1.

49.

Primary lymphoma of bone: outcome and role of surgery.

Scoccianti G, Rigacci L, Puccini B, Campanacci DA, Simontacchi G, Bosi A, Capanna R.

Int Orthop. 2013 Dec;37(12):2437-42. doi: 10.1007/s00264-013-2055-6. Epub 2013 Aug 24.

50.

Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.

Fabbri A, Cencini E, Rigacci L, Bartalucci G, Puccini B, Dottori R, Gozzetti A, Bosi A, Bocchia M.

Leuk Lymphoma. 2014 Apr;55(4):781-5. doi: 10.3109/10428194.2013.826354. Epub 2014 Jan 24.

PMID:
23876098

Supplemental Content

Loading ...
Support Center